Grand Pharmaceutical Group Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Grand Pharmaceutical Group has a total shareholder equity of HK$15.9B and total debt of HK$4.5B, which brings its debt-to-equity ratio to 28.1%. Its total assets and total liabilities are HK$24.9B and HK$9.0B respectively. Grand Pharmaceutical Group's EBIT is HK$3.0B making its interest coverage ratio 17.8. It has cash and short-term investments of HK$3.2B.
Anahtar bilgiler
28.1%
Borç/özkaynak oranı
HK$4.47b
Borç
| Faiz karşılama oranı | 17.8x |
| Nakit | HK$3.23b |
| Eşitlik | HK$15.90b |
| Toplam yükümlülükler | HK$9.00b |
| Toplam varlıklar | HK$24.90b |
Son finansal sağlık güncellemeleri
We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt
Oct 20
Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?
May 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Nov 21Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Aug 16Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet
Mar 22These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely
Dec 13Recent updates
Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 19Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year
Jun 05Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings
May 22Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Apr 25Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Mar 25We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt
Oct 20Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Sep 26Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14
Jun 04Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?
May 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Nov 21Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?
Sep 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Aug 16Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Jul 28Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11
May 29Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?
Apr 08Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet
Mar 22If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late
Jan 24These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely
Dec 13Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price
Nov 27With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting
Oct 25China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly
Sep 01Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?
Jul 12Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 512's short term assets (HK$8.2B) exceed its short term liabilities (HK$6.4B).
Uzun Vadeli Yükümlülükler: 512's short term assets (HK$8.2B) exceed its long term liabilities (HK$2.6B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 512's net debt to equity ratio (7.8%) is considered satisfactory.
Borcun Azaltılması: 512's debt to equity ratio has reduced from 29.4% to 28.1% over the past 5 years.
Borç Kapsamı: 512's debt is well covered by operating cash flow (42.6%).
Faiz Kapsamı: 512's interest payments on its debt are well covered by EBIT (17.8x coverage).